$FLGT on NASDAQ
February 09, 2024
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
November 14, 2023
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 03, 2023
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
November 03, 2023
Fulgent Reports Third Quarter 2023 Financial Results
October 25, 2023
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
October 17, 2023
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
August 04, 2023
Fulgent Reports Second Quarter 2023 Financial Results
July 18, 2023
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
June 05, 2023
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
May 18, 2023
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
May 05, 2023
Fulgent Reports First Quarter 2023 Financial Results
April 20, 2023
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
April 11, 2023
Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research
February 28, 2023
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
February 23, 2023
Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
February 14, 2023
Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
January 03, 2023
Fulgent Expands Board of Directors with Addition of Reggie Groves
November 17, 2022
Fulgent Genetics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
November 07, 2022
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
November 07, 2022
Fulgent Genetics Reports Third Quarter 2022 Financial Results
October 25, 2022
Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference
October 20, 2022
Fulgent Genetics to Announce Third Quarter 2022 Financial Results on Monday November 7, 2022
August 04, 2022
Fulgent Genetics Reports Second Quarter 2022 Financial Results
August 04, 2022
Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox
August 04, 2022
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
July 19, 2022
Fulgent Genetics to Announce Second Quarter 2022 Financial Results on Thursday, August 4, 2022
July 05, 2022
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test
April 27, 2022
AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC.
April 18, 2022
Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results
April 18, 2022
Fulgent Genetics to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
March 08, 2022
Representatives of Fulgent Genetics to Participate in Oppenheimer’s 32nd Annual Healthcare Conference
March 08, 2022
Fulgent Genetics Announces $250 Million Share Repurchase Program
March 07, 2022
Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer
February 24, 2022
EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS
February 23, 2022
Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Fulgent Genetics Announces Strategic Investment in Spatial Genomics
February 14, 2022
Fulgent Genetics to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday February 23, 2022
December 06, 2021
HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available
December 01, 2021
Fulgent Genetics Confirms Ability to Detect Omicron Variant with RT-PCR Tests for COVID-19
November 09, 2021
Fulgent Genetics Reports Third Quarter Financial Results
November 09, 2021
Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences
November 08, 2021
Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiver™ for Early Liver Cancer Detection
November 01, 2021
Helio Health and Fulgent Genetics to Present New Data on HelioLiver in Late-Breaking Presentation at The Liver Meeting® 2021
October 27, 2021
Fulgent Genetics Launches At-Home Neutralizing Antibody Test for COVID-19
October 25, 2021
Fulgent Genetics to Announce Third Quarter 2021 Financial Results on Tuesday November 9, 2021
September 23, 2021
Fulgent Genetics to Partner with Houston Health Department and Houston-Area Public Schools on Back-to-School COVID-19 Testing Program
August 09, 2021
Fulgent Genetics Reports Second Quarter Financial Results
August 09, 2021
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests
August 09, 2021
Fulgent Genetics Announces Acquisition of CSI Laboratories
- No Recent Filings Found.
